Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 8/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.57 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.56 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.53 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25199114 | 0.85 | CYSLTR1 (0.54) | NR4A2NPC1RAB9AALKBH1FFAR1 | |
| SCHEMBL6206160 | 0.84 | SPHK2 (0.50) | NR4A2NPC1RAB9AALKBH1FFAR1 | |
| SCHEMBL6206165 | 0.84 | SPHK2 (0.50) | NR4A2NPC1RAB9AALKBH1FFAR1 | |
| SCHEMBL6206166 | 0.84 | SPHK2 (0.50) | NR4A2NPC1RAB9AALKBH1FFAR1 | |
| SCHEMBL15607572 | 0.82 | FFAR1 (0.52) | NR4A2NPC1RAB9AALKBH1FFAR1 | |
| SCHEMBL9270379 | 0.82 | FFAR1 (0.64) | ALKBH1FFAR1SPHK2SPHK1XDH | |
| SCHEMBL1794163 | 0.82 | ALKBH1 (0.54) | NR4A2NPC1RAB9AALKBH1FFAR1 | |
| SCHEMBL30391934 | 0.81 | SPHK2 (0.48) | NR4A2NPC1RAB9AALKBH1FFAR1 | |
| SCHEMBL25720523 | 0.81 | SPHK2 (0.48) | NR4A2NPC1RAB9AALKBH1FFAR1 | |
| SCHEMBL25208110 | 0.80 | FFAR1 (0.48) | NR4A2NPC1RAB9AALKBH1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051300-A1 | GRAM-NEGATIVE SPECIFIC ANTIBIOTICS SPARING EFFECT ON GUT MICROBIOME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2023091873-A1 | GRAM-NEGATIVE SPECIFIC ANTIBIOTICS SPARING EFFECT ON GUT MICROBIOME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091873-A1 | GRAM-NEGATIVE SPECIFIC ANTIBIOTICS SPARING EFFECT ON GUT MICROBIOME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-05-25 | — | — | WO | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051300-A1 | GRAM-NEGATIVE SPECIFIC ANTIBIOTICS SPARING EFFECT ON GUT MICROBIOME | ABCE1, LDLR, LIPE | NR4A2 2665/4885NPC1 243/4885RAB9A 895/4885 |
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | NR4A2 2186/4885NPC1 1139/4885RAB9A 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.